Brandon Scalea

Articles

Padda Discusses Progress With Osimertinib and Next Steps in EGFR+ NSCLC

February 5th 2019

Sukhmani Padda, MD, discusses the practice-changing impact of osimertinib and addresses the challenges that still remain in EGFR-positive NSCLC.

SM-88 Shows Promise in Advanced Pancreatic Cancer

January 31st 2019

Allyson J. Ocean, MD, discusses the potential impact of SM-88 in the treatment of patients with advanced pancreatic cancer and highlights a platform that patients can use to stay updated on the latest research in the field.

Expert Expects T-DM1 to Transform Treatment in HER2+ Breast Cancer

January 29th 2019

Charles E. Geyer, Jrm, MD, discusses the clinical implications of the KATHERINE trial and the outlook for T-DM1 in patients with HER2-positive breast cancer.

Socinski Says Immunotherapy, Targeted Therapy Have Altered Outlook in NSCLC

January 29th 2019

Mark A. Socinski, MD, provides an overview of treatment advances in the lung cancer landscape, and highlights where much-needed work still remains.

Radiation Could Aid in Increasing Pancreatic Cancer Resections

January 28th 2019

Amol K. Narang, MD, discusses recent advances made in the treatment of pancreatic cancer and explained how radiation oncology can be used to provide further clinical benefit to this patient population.

Surgery Maintains Role in Rapidly Advancing Lung Cancer Treatment Paradigm

January 28th 2019

Eric Vallieres, MD, highlights the technological advances of lung cancer surgery and how this impacts the outlook for patients who are candidates for it.

Lilenbaum Examines EGFR+ NSCLC Advancements and Potential Role of Immunotherapy

January 27th 2019

Rogerio Lilenbaum, MD, highlights the current treatment approaches for patients with EGFR-positive non–small cell lung cancer and shed light on the potential for immunotherapy in the space.

Chari Highlights Emerging Options in Heavily Pretreated Myeloma

January 26th 2019

Ajai Chari, MD, discusses novel treatment approaches for patients with heavily pretreated multiple myeloma.

Lead Investigator Says Tisagenlecleucel Has Changed Natural History of DLBCL

January 23rd 2019

Richard T. Maziarz, MD, discusses the updated findings from JULIET and their clinical implications for patients with diffuse large B-cell lymphoma.

Bekaii-Saab Brings Insight to Precision Medicine in GI Cancers

January 23rd 2019

Tanios Bekaii-Saab, MD, discusses ways to further develop precision medicine within the treatment of patients with gastrointestinal cancers.

Choti Sheds Light on Research Developments in Pancreatic Cancer

January 22nd 2019

Michael A. Choti, MD, highlights ongoing developments in the field of pancreatic cancer.

Abou-Alfa Highlights HCC Advances, Unmet Needs in Other GI Cancers

January 16th 2019

Ghassan K. Abou-Alfa, MD, discusses the rapidly evolving treatment options in hepatocellular carcinoma and other developments in gastrointestinal cancers.

Navigating the Complex Paradigm of Oncogene-Driven NSCLC

January 16th 2019

Lara Kujtan, MD, sheds light on how to navigate the complex paradigm of oncogene-driven non–small cell lung cancer and stressed the importance of patient preferences when deciding on optimal treatment approaches.

Strategies Needed for Resistance to Targeted Agents in HER2+ Breast Cancer

January 15th 2019

Mothaffar F. Rimawi, MD, discusses the current options in HER2-positive breast cancer and sheds light on where future research is headed.

Daratumumab/VRd Regimen Has Practice-Changing Potential in Myeloma

January 12th 2019

Peter Voorhees, MD, discusses the clinical potential of adding daratumumab to bortezomib, lenalidomide, and dexamethasone in patients with multiple myeloma.

Following bb2121, Novel CAR T-Cell Product Shows Potential in Myeloma

January 12th 2019

Nina Shah, MD, discusses the promise of bb21217 in the complex treatment paradigm of relapsed/refractory multiple myeloma

Few Unanswered Questions Remain for Nonmetastatic Prostate Cancer

January 11th 2019

Harsha Ranganath, MD, discusses the current and future treatment of patients with nonmetastatic castration-resistant prostate cancer.

Pomalidomide Shows Benefit in Lenalidomide-Refractory Myeloma

January 11th 2019

David S. Siegel, MD, PhD, discusses a potentially practice-changing trial in multiple myeloma.

Expert Explores Future of CDK4/6 Inhibitors in Breast Cancer

January 11th 2019

Matthew P. Goetz, MD, discusses the impact of CDK4/6 inhibitors and their future role in the treatment of hormone receptor–positive breast cancer.

Radiation Oncologist Reflects on Traditional Treatment Modalities in Prostate Cancer

January 10th 2019

Holger L. Gieschen, MD, discusses the role of radiation therapy in prostate cancer and ongoing efforts to further refine this strategy.